[Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months]

Strahlenther Onkol. 2019 Aug;195(8):764-766. doi: 10.1007/s00066-019-01470-5.
[Article in German]
No abstract available

Publication types

  • Comment

MeSH terms

  • Androgen Antagonists
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms*
  • Risk Factors

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen